Los Angeles Capital Management LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Los Angeles Capital Management LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 67.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,943 shares of the medical research company’s stock after selling 44,730 shares during the period. Los Angeles Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $11,647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Raleigh Capital Management Inc. lifted its holdings in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares during the period. Cedar Mountain Advisors LLC lifted its position in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares during the last quarter. Operose Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the last quarter. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. increased its stake in Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 32 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Raymond James boosted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Finally, HSBC upped their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $607.35.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold 62,277 shares of company stock worth $35,373,364 in the last three months. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.2 %

Shares of TMO opened at $572.38 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a fifty day simple moving average of $575.39 and a two-hundred day simple moving average of $532.82. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a market capitalization of $218.48 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.